Oxford BioMedica (OXB), a British gene and cell therapy group, announced the formation of a new digital framework initiative to streamline the production of next-generation medicines.
The group will invest a total of £4 million, supported by a £2 million grant from Innovate UK, in building digital and robotics capabilities designed to drive improvements in analytical methodology, supply times and cost of goods.
The aims of the project are aligned with the UK Government’s Life Sciences Sector Deal to help ensure that the next wave of breakthrough treatments, innovative medical research and technologies, and high skill jobs are created in Britain.
OXB has recently announced the expansion of its manufacturing capacity to create an additional facility near its headquarters in Oxford (UK). This new facility will become a bioprocessing centre for OXB and will create up to 100 new, highly skilled positions over the next two years.
This new initiative will provide digital and robotic enhancements to maintain global leading position in the development and manufacture of lentiviral vector products. This is important for R&D pipeline as it continues to support the delivery of life-altering gene therapies to patients around the world.
CSV Containment is present in the pharmaceutical market and is focused on providing engineering, construction and validation solutions for the LifeScience world. For more information: email@example.com